CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Early and sustained symptom control with mirikizumab in patients with moderately to severely active ulcerative colitis in the LUCENT phase 3 clinical trial program
DOI 10.1055/s-0043-1771744
Bibliografische Angaben
Nachweis in CareLit
Autor:innenA. Dignass, S. Danese, K. Matsuoka, M. Ferrante, M. Long, I. Redondo, S. Maier, T. H. Gibble, R. Moses, N. Morris, X. Li, M. T. Abreu
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe08/2023
Jahrgang / SeitenJg. 61 · S. e417-e419
Kernaussage aus der Literatur
Abstract-Vorschau
Early and sustained symptom control with mirikizumab in patients with moderately to severely active ulcerative colitis in the LUCENT phase 3 clinical trial program
Zitieren
Zitierempfehlung
A. Dignass, S. Danese, K. Matsuoka, M. Ferrante, M. Long, I. Redondo, S. Maier, T. H. Gibble, R. Moses, N. Morris, X. Li, M. T. Abreu (2023) Early and sustained symptom control with mirikizumab in patients with moderately to severely active ulcerative colitis in the LUCENT phase 3 clinical trial program. Zeitschrift für Gastroenterologie, 61 (08), e417-e419. https://doi.org/10.1055/s-0043-1771744
Mit CareLit weiterarbeiten